ROCK2 and chronic myelogenous leukemia, BCR-ABL1 positive: At centrosomes, morgana/chp-1 directly binds ROCK2 and prevents ROCK2 activation by nucleophosmin; the down-regulation of morgana in mice or in patients with atypical chronic myeloid leukemia leads to increased ROCK2 kinase activity, which results in centrosome amplification and cytogenetic abnormalities (Di Savino et al. 2015; Ferretti et al. 2010).